Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare Payment Policy For Dialysis Drugs Seeks To Promote Innovation, Restrain Costs

Executive Summary

More new dialysis drugs would be eligible for Medicare add-on payments under proposed rule, but payment amounts would be lower.

You may also be interested in...



Medicare Payments For Sensipar, Parsabiv Could Be Bellwether For Dialysis Drug Developers

Sensipar/Parsabiv marketer Amgen and three developers of new treatments for anemia emphasize importance to innovation of additional payments outside  Medicare's reimbursement bundle for end-stage renal disease.

Roxadustat To Overtake Epogen In Treating Anemia In CKD By 2021

The market for the treatment of anemia in chronic kidney disease will see Epogen eroded by biosimilars before the overall segment finally returns to growth following the launch of HIF-PHI inhibitor roxadustat, according to Datamonitor Healthcare's latest forecast.

Emerging Dialysis Drugs Will Face Medicare Reimbursement Challenges

Navigating Medicare's complicated bundled payment system could be tricky for new class of anemia drugs, the HIF prolyl hydroxylase inhibitors, which may start to reach the market for dialysis patients in 2019.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS123486

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel